Endometrial scratching prior to first cycle of in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) has no benefit on livebirth or clinical pregnancy rate, according to a study presented at ESHRE 2020.
Relugolix combination therapy (relugolix-CT) comprising relugolix and estradiol (E2)/norethindrone acetate (NETA) could improve anaemia in women with heavy menstrual bleeding (HMB) due to uterine fibroids, according to pooled results of the phase III LIBERTY* 1 and 2 trials presented at ESHRE 2020.
The incidence of cerebral palsy among children conceived through in vitro fertilization (IVF) has been halved over the past two decades, although the risk of cerebral palsy remains higher than children who are conceived naturally, according to a Nordic study presented at the ESHRE 2020 Meeting.
De-escalating the BEACOPPescalated* regimen through a PET-driven strategy may reduce the risk of acute premature ovarian insufficiency (POI) in women with newly diagnosed advanced Hodgkin lymphoma (HL), subanalysis results of the phase III AHL2011 trial have shown.
Children who were born after freeze-only embryo transfer (ET) experienced improved early developmental outcomes, particularly problem solving and fine motor skills, than those who were born after fresh ET, according to a follow-up study presented at ESHRE 2020.
Female cancer survivors who undergo fertility preservation before cancer treatment often use their stored gametes/embryos. This highlights the effectiveness of pre-cancer fertility preservation, according to a study presented at ESHRE 2020.
The use of linzagolix, a new oral gonadotropin-releasing hormone (GnRH) antagonist, with or without add-back therapy (ABT) significantly reduces heavy menstrual bleeding (HMB) in women with uterine fibroids, according to the PRIMROSE 2* trial presented at ESHRE 2020.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.